近期癌症诊断对心肌梗死后出血风险的影响
逆概率加权分析显示,癌症患者心梗后第一年出血住院风险显著高于非癌症患者(HR 1.53,95%CI 1.45-1.62,p<0.001),第二年风险仍持续升高(HR 1.42,95%CI 1.29-1.56,p<0.001),且不同癌症类型间出血风险存在明显差异。
要点
- 心梗合并癌症患者第一年出血住院风险较非癌症患者增加53%。
- 第二年出血风险仍持续升高,较非癌症患者增加42%。
- 不同癌症类型间出血风险存在明显差异,需个体化评估。
核心结论
- 合并癌症的心肌梗死患者在第一年出血风险增加,第二年有所下降但仍持续存在。
- 心梗后必须仔细评估癌症患者的出血风险。
研究设计与样本
- 真实世界观察性研究,数据来自英格兰国家心脏肿瘤数据库,纳入2006至2019年心肌梗死患者。
- 采用逆概率加权进行时间-事件分析,随访最长24个月,结局为因大出血事件住院就诊。
主要发现
- 心梗后第一年出血住院率癌症患者高于非癌症参照人群(HR 1.53,95%CI 1.45-1.62,p<0.001)。
- 心梗后第二年癌症患者出血率仍升高(HR 1.42,95%CI 1.29-1.56,p<0.001)。
- 不同癌症类型间出血风险存在显著差异。
- 最常见癌症类型为结直肠癌、前列腺癌、乳腺癌、肺癌和膀胱癌。
临床怎么用
- 对心梗合并癌症患者,应仔细评估出血风险,尤其是在心梗后第一年和第二年。
- 需考虑癌症类型对出血风险的影响,实施个体化抗栓治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Determining the most appropriate treatment in patients with cancer with an acute myocardial infarction (MI) can be challenging. Optimal management requires an understanding of bleeding risk which may be different in this population. This study aimed to investigate the bleeding risk among patients with MI with and without cancer, in the first and second year post-MI. METHODS: Patients with MI, with and without cancer were identified from a national cardio-oncology database from England between 2006 and 2019. The outcome was a presentation to hospital for a major bleeding event, with patients followed for a maximum of 24 months. Inverse probability weighting was used to compare cancer and non-cancer cohorts in time-to-event analyses. RESULTS: 587 279 patients with MI were identified, 9820 (1.7%) had cancer and 577 459 (98.3%) did not. Colorectal, prostate, breast, lung and bladder cancer were the most common types of cancer. The rate of hospital presentation for bleeding in the first year post-MI was higher in patients with cancer than the non-cancer reference population (HR: 1.53, 95% CI 1.45 to 1.62, p<0.001). 506 280 patients with MI were followed up in the second year post-MI. 5666 (1.1%) had cancer and 500 614 (98.9%) did not. The bleeding rate in patients with MI with cancer remained elevated in the second year post-MI (HR: 1.42, 95% CI 1.29 to 1.56, p<0.001). There were marked differences in bleeding between cancer types. CONCLUSION: In this real-world observational study, patients with cancer had an increased bleeding risk in the first year post-MI which decreased but persisted in the second year after MI. Bleeding risk in patients with cancer must be carefully assessed post-MI.
引用
- Ow, Tyrer, Van Den Berg, et al. Impact of a recent cancer diagnosis on bleeding risk after myocardial infarction. Heart. 2026. PMID: 41469213. doi:10.1136/heartjnl-2025-326524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。